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Abstract. Parkinson’s disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a
subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully
understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics.
Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different
reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and
increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD
patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in
PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of
glycated proteins may also prove beneficial for PD patients.
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PARKINSON’S DISEASE IS A MULTI-
FACTORIAL DISEASE WITH UNCLEAR
ETIOLOGY
Parkinson’s disease (PD), the second most com-
mon neurodegenerative disease, is typically known
for the loss of dopaminergic neurons in the substan-
tia nigra pars compacta and for the occurrence of
∗Correspondence to: Prof. Dr. Tiago Fleming Outeiro, Depart-
ment of Experimental Neurodegeneration, University Medical
Center Go¨ttingen, 37073 Go¨ttingen, Germany. E-mail: touteir@
gwdg.de.
Lewy bodies and Lewy neurites (intracellular pro-
teinaceous inclusions) in the surviving cells [1]. Since
its initial description by James Parkinson in 1817,
it is now widely accepted that PD is not simply a
movement disorder. Apart from the defining motor
features—rigidity, resting tremor, bradykinesia, and
disturbed gait—the majority of PD patients also expe-
riences one or several non-motor features that may
precede the onset of motor symptoms by decades.
Non-motor features include olfactory dysfunction,
constipation and other disturbances of the diges-
tive system, REM behaviour disorders, dementia,
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cognitive decline, anxiety and depression [2]. The
observation that Lewy-body pathology and other
pathological changes can be detected in the gut and/or
in the olfactory system many years before motor-
features, led to the hypothesis that the PD-pathology
spreads from the peripheral nervous system to the
CNS [3].
PD is an extremely heterogeneous disorder, with
different ages of onset, progression rate, pathology
and disease manifestation. Thus, several disease sub-
types are pooled together as PD [4]. In addition,
several related disorders including multiple systems
atrophy and dementia with Lewy bodies share com-
mon features with PD. The classification of PD is
often based on motor features, but non-motor fea-
tures and age of onset are also used to sub-classify
PD cases [2]. However, a definitive detailed catego-
rization of PD cases is still not consensual. Attempts
to classify PD cases based on more objective tests
such as biomarkers or neuroimaging are expected to
lead to major advances in the field. Subdividing PD
into sporadic and monogenic forms has already led to
the identification of groups with more similar clinical
features. Extending this effort to ensure improved dis-
crimination between subtypes of PD will also prove
critical both for fitting therapeutic approaches to indi-
vidual patients, and for discovering the molecular
underpinnings of PD pathology, which may in turn
constitute novel targets for therapeutic intervention.
Most PD cases are sporadic, and only 5–10% have
a known genetic cause and can be ascribed to muta-
tions in single genes [1]. The first gene associated
with monogenic PD was SNCA, encoding for the pro-
tein alpha-synuclein (aSyn), the main component of
Lewy bodies and Lewy neurites, thought to play a
central role in the disease [5, 6].
A number of genetic and environmental risk
factors for PD/parkinsonism have been identified
over the years. For example, the exposure to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
was found to cause a PD-like disease [7]. Other envi-
ronmental risk factors, such as rural living, well water
consumption, exposure to pesticides or solvents, were
also associated with some forms of parkinsonism
[8–10]. On the other hand, coffee or nicotine con-
sumption are associated with a decreased risk to
develop PD [11, 12]. Given that the majority of PD
cases are caused by a combination of both genetic
and environmental factors, it is critical to analyse
in detail the impact of these environmental fac-
tors on the molecular mechanisms that lead to PD
pathology. In this context, glycation emerges as a
possible environmental factor that can impact on PD
pathogenesis.
GLYCATION OF PROTEINS: AN
UNAVOIDABLE PROCESS
Glycation, via the Maillard reaction, named after
Louis C. Maillard who first described the browning
processes in food processing [13], involves the non-
enzymatic reaction of reducing carbohydrates and
amino compounds. In fact, it is not a single reaction
but a complex series of reactions that was studied
for decades, mainly in the context of food brown-
ing and is lately also receiving attention due to its
role in neurodegenerative diseases [14, 15]. These
Maillard reactions were characterized and grouped
into a scheme [16]. In the first step, a carbonyl group
(from glucose or other reactive carbonyl species) con-
denses with an amino or thiol group of amino acids,
nucleic acids or amino lipids, giving rise to an early
glycation product termed Amadori compound. In the
second step of the reaction, the intermediate Amadori
compound is rearranged and breaks down in one
of several possible chemical pathways. A variety of
different carbonyl and dicarbonyl intermediate prod-
ucts, including glyoxal and methylglyoxal (MGO)
are formed, and can exist free or bound to proteins.
Lastly, higher molecular weight species (advanced
glycation end products (AGEs)) are formed from
these lower molecular weight intermediates [17].
Importantly, other pathways and mechanisms includ-
ing oxidative stress also contribute to the formation of
reactive carbonyl species [18]. As mentioned above,
glycation can affect various biomolecules. While
proteins are important targets of glycation (the N-
terminal residue, the amino group of lysine residues,
and the guanidinium group of arginine residues can
be subject to Maillard modifications), DNA [19, 20]
and lipids [21] can also be subject to glycation.
The term “glycation” is often used in a rather
imprecise manner. It is frequently used to distinguish
the non-enzymatic reaction from the enzymatic gly-
cosylation of proteins that go through the secretory
pathway. Furthermore, glycation may refer specifi-
cally to the formation of an Amadori product, via the
reaction of an amino acid with glucose. But the term
glycation is also used to describe the addition of car-
bonyls, such as MGO, to proteins and the formation
of AGEs. This inconsistent nomenclature reflects the
lack of in-depth understanding of the mechanisms
and physiological roles of these reactions.
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The most abundant AGEs are MGO-derived
hydroimidazolone 1, the lysine arginine cross-link
glucosepane and N()-carboxymethyllysine (CML)
[22]. However, it is critical to appreciate that the
Maillard reaction network can give rise to hundreds
or thousands of different products. The reaction of
only one sugar with one amino acid was recently
shown to lead to the formation of up to 300 prod-
ucts [23], and this immense variety of adducts with
different characteristics complicates the study of
Maillard reactions. A variety of methods have been
applied to study the non-enzymatic reaction of reduc-
ing carbonyls and amino compounds. Given that a
number of AGEs are fluorescent, it is possible to
follow their formation simply by measuring their
fluorescence. Furthermore, the availability of anti-
bodies directed to different AGEs enables the analysis
of the localization of AGEs in cells and tissues
using immunochemical methods [24]. In addition,
mass spectrometry techniques are crucial for assess-
ing glycation products, especially since advances in
untargeted mass spectrometry enable the detection of
a larger number of molecules [25, 26].
The levels of AGEs in a given tissue are deter-
mined by the formation rate, the stability of the
resulting AGE, and the turnover of the target pro-
tein. Even though there are differences between the
various routes of the Maillard reaction, the reaction
is generally rather slow, and the reaction products are
very stable [17]. The degree to which an individual
protein undergoes Maillard modifications depends on
the amount of precursors and the availability of poten-
tial target sites for the modification [22]. While long
lived proteins have the chance to accumulate many
AGEs, degradation of short lived proteins releases
free, non-protein bound AGEs [27].
The majority of dicarbonyls are catabolized
by the glyoxalate system, comprising the highly
abundant glyoxalases Glo1 and Glo2. MGO is
converted to D-lactate in a glutathione-dependent
reaction [28]. Other systems that protect cells
from carbonyl stress involve aldo-ketoreductases,
aldehyde-dehydrogenase and fructosamin-3-kinases
[29, 30]. Interestingly, DJ-1, the product of the
PARK7 gene that is associated with recessive forms
of PD, was recently shown to be associated with
glycation. DJ-1 displays various cellular roles,
including chaperone function, response to oxidative
stress, and glyoxalase activity [31–33]. In addition,
it was suggested that DJ-1 can deglycate MGO-
and glyoxal-modified amino acids, nucleotides, and
nucleic acids [19, 34]. However, these studies remain
controversial [35], and the physiological role of DJ-1
as a deglycase remains to be confirmed.
DIABETES AS A RISK FACTOR FOR PD
Diabetes has been suggested as a risk factor for PD
and other neurodegenerative disorders. Recent stud-
ies suggest that diabetes increases the risk for PD
by 23% [36]. After adjusted hazard ratio, a larger
magnitude was observed in females, and only dia-
betic patients over 65 years-old showed increased risk
for PD [36]. In this study, diabetes duration was not
considered. However, in the Neurological Disorders
in Central Spain (NEDICES) study, which included
4919 controls (828 with diabetes) and 79 PD patients
(14 with diabetes), the duration of diabetes emerged
as an important factor in the association between PD
and diabetes. The increased risk might be limited to
those with longer disease duration (>10 years) [37].
This was also previously observed in a cohort in the
U.S.A. [38]. Nevertheless, it is now established that
diabetes prior to PD increases the risk for more severe
PD features [39].
Several meta-analysis studies have evaluated dia-
betes as a risk factor for PD. For example, a recent
association study, including a total of 7 population-
based cohort studies, further suggests that diabetes
is associated with a 38% increase in PD risk [40].
This meta-analysis is consistent with previous stud-
ies [38, 41, 42]. Intriguingly, some reports found no
association between diabetes and PD [43–47].
Likewise, PD diagnostic, severity, progression and
medication should also be considered.
In a recent genome-wide association study
(GWAS) to assess the association between immune-
mediated diseases and PD, 4 genetic loci were found
to be shared between PD and type 1 diabetes [48].
Further evidence linking diabetes with PD comes
from prospective studies where diabetes is found to
contribute to the development of PD. For example,
one of the non-motor features associated with PD is
mild cognitive impairment (MCI) [49]. PD patients
with diabetes display reduced cortical grey matter,
amygdala, frontal white matter and temporal white
matter volumes, and higher total white matter hyper-
intensity and periventricular hyperintensities. This
occurs regardless of the duration of PD [50, 51].
In a longitudinal study, PD patients with diabetes
presented a higher rate of atrophy in the cortical
white matter, particularly in the parietal and occipital
white matter. These patients also presented a greater
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decline in Mini-Mental State Examination (MMSE)
and Montreal Cognitive Assessment (MoCA) scores,
tests aimed to screen for dementia or MCI [50, 52].
ALTERED HOMEOSTASIS OF SUGAR
METABOLISM IS A COMMON FEATURE
BETWEEN DIABETES AND PD
The deleterious effects of high neuronal glucose
in diabetic conditions are well known. While the
brain weighs approximately 2% of the whole body,
it accounts for about 20% of the whole energy con-
sumption. Neurons have a constantly high demand
for glucose as the preferred energy source. However,
neurons can only store minimal amounts of glucose
intracellularly [53]. The glucose transporters GLUT1
and GLUT3, that are mainly expressed in the blood
brain barrier and in neurons, respectively, efficiently
take up glucose from the blood into brain and neu-
rons. Importantly, their function is not modulated
by insulin. While certain brain areas also express
the insulin dependent GLUT4, it appears that glu-
cose uptake in the brain is insulin-independent [54].
Accordingly, several reports confirmed that intrac-
erebral glucose levels depend solely on those in the
plasma in rat and humans [55–57] and it is estimated
that the glucose levels in neurons and in the extracel-
lular space are identical [56]. Thus, neurons appear to
be particularly exposed to fluctuating glucose levels.
Intracellular glucose is normally phosphorylated
to glucose-6-phosphate to enter glycolysis or the
pentose phosphate pathway. However, high glucose
levels lead to diverging metabolic routes giving rise to
reactive dicarbonyl species [58]. Despite advances in
the adjustment of blood sugar levels, diabetes patients
frequently experience persisting hyperglycemia, or
reoccurring episodes [58]. Accordingly, the levels
of reactive dicarbonyls and AGEs were shown to
be elevated in diabetes patients and in experimental
models of diabetes [59, 60]. Even though the overall
dicarbonyl concentration in tissue is not high, dicar-
bonyls are significantly more reactive than glucose
[17, 61]. Interestingly, glycation of proteins is thought
to be a main cause of several diabetic complications
including retinopathy, neuropathy, and nephropathy,
and the AGE content in tissues enables predictions
about the severity and the occurrence of diabetic
complications [62].
Both glucose and MGO levels are elevated in dia-
betes. However, their ratios are still a subject of
discussion, and it is suggested that, in addition to
hyperglycemia, other metabolic changes contribute
to elevated MGO concentrations [63]. Indeed, Glo1
levels were shown to be decreased in several
PD models and in PD patients [64]. Further-
more, Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), a glycolytic enzyme that constitutes
5–20% of total soluble cytoplasmic protein, is sub-
ject to glycation, leading to its inactivation. In turn,
GAPDH inactivation and altered glycolysis levels
lead to redirection of the glucose flux towards the
pentosephosphate-pathway, possibly also increasing
the rate of dicarbonyl formation [65].
It was also suggested that insulin itself may also
bind MGO [58]. Altogether, these findings suggest
a critical role of MGO in the global impairment of
energy metabolism in diabetes. While hyperglycemia
can, in many cases, be corrected, glycation of tis-
sue proteins accumulates over their lifetimes, thereby
contributing to the chronic complications that many
diabetes patients experience (Fig. 1).
Several studies reported a dysregulation of sugar
metabolism in PD. Glucose-6-phosphate dehydro-
genase and 6-phosphogluconate dehydrogenase, key
enzymes in the pentose-phosphate pathway, are
decreased in post-mortem PD brains [66]. PD
patients display decreased glucose tolerance and
hyperglycemia. Furthermore, elevated levels of the
monosaccharides fructose and mannose are present
in the cerebrospinal fluid of early-stage PD patients
[67, 68]. Along this line, aSyn deficient mice
display altered AGEs and increased Glo1 activ-
ity, further illustrating aSyn involvement in sugar
metabolism [69].
Several human diseases, including PD, are asso-
ciated with protein misfolding and aggregation [70].
aSyn, a key player in PD, is a long-lived protein and,
therefore, is likely to be glycated over time [71]. In
fact, AGEs colocalize with aSyn in Lewy bodies in the
substantia nigra [72, 73], and we have recently iden-
tified glycated aSyn in brain tissue from PD patients
[74]. Furthermore, it was shown that aSyn can be gly-
cated in vitro, in the N-terminal region, by dicarbonyl
compounds and ribose [74–76].
The physiological function of aSyn is affected
by glycation in several ways: It was shown both
in human cell lines and in animal models that gly-
cated aSyn is more prone to oligomerization (Fig. 2)
[74, 76, 77]. Furthermore, studies in a PD cell mod-
els revealed that glycated aSyn displays reduced
mono-ubiquitination, proteasome- and autophagy-
lysosome-mediated degradation [74]. In addition,
MGO-treatment was shown to lead to reduced aSyn
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Fig. 1. AGEs accumulate due to recurring or chronic hyperglycemia. The glucose transporters Glut1 and Glut3 that are expressed in the
blood-brain barrier and neurons, respectively, shuttle glucose in an insulin-independent manner. In hyperglycemic conditions, intracerebral
glucose levels also increase, which in turn increases glycation and AGEs accumulating especially in long-lived proteins. DM, diabetes
mellitus.
release and impaired binding to lipid membranes, fur-
ther contributing to accumulation of aSyn inside cells
[74]. Interestingly, aSyn physiology is not just altered
directly by glycating agents. Actually, the presence
of AGEs produced, for example, from bovine serum
albumin, induces the cross-linking of aSyn [78].
Despite progress made on unrevealing the complex
effects of glycating agents on aSyn physiology and
pathology, a number of questions remain.
DOPAMINE AND MGO: PARTNERS IN
CRIME
The loss of dopaminergic cells in the substan-
tia nigra pars compacta is a hallmark of PD, but
it is unclear why this particular type of dopamin-
ergic neurons appear particularly more vulnerable.
The “auto-toxicity theory” suggests that dopamine
products itself are responsible for the degeneration of
dopaminergic neurons. The catecholamine dopamine
can undergo several chemical transformations that
give rise to toxic molecules. In particular, sponta-
neous oxidation leads to the formation of reactive
oxygen species and quinones. Enzymatic oxidation
of dopamine catalysed by monoamine oxidase gives
rise to a highly toxic and reactive intermediate com-
pound: 3,4-dihydrox-yphenylacetaldehyde (DOPAL)
[79]. Dopamine-derived quinones were shown to
react with several proteins implicated in PD, includ-
ing aSyn, parkin, DJ-1 [80–82]. Interestingly, it was
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Fig. 2. Glycation affects aSyn conformations. aSyn is the predom-
inant component of Lewy bodies. During the aggregation process,
aSyn monomers start to assemble into dimers, oligomers, and
eventually into -sheet containing fibrils. Oligomers are currently
thought to be the most toxic species. Interestingly, the levels of
reactive dicarbonyls (GO, glyoxal; MGO, methylglyoxal) increase
upon hyperglycemia, and may potentiate aSyn oligomerization,
while inhibiting its fibrillization, and lead to the accumulation of
toxic glycated aSyn oligomers.
shown that DOPAL leads to the oligomerization of
aSyn which alters synaptic vesicle homeostasis [83].
DOPAL can be metabolized enzymatically by alde-
hyde dehydrogenase. Dopamine-derived metabolites
share reactive groups with MGO: dicarbonyl groups
drive the reaction with amino groups of proteins
and the catechol moiety can induce cross-linking
of proteins. Altogether, dopamine-derived products
have a similar structure and mode of action as MGO
and, therefore, have to be taken into consideration
as well when discussing the importance of reactive
dicarbonyls.
AN INTRIGUING OBSERVATION:
ANTI-DIABETIC DRUGS HAVE
BENEFICIAL EFFECTS IN PD
Given the commonalities between PD and dia-
betes, it is tempting to speculate, that anti-diabetic
drugs may also prove beneficial in PD. In fact, there
are already examples of such drugs.
As mentioned above, diabetes is associated with
the accumulation of AGEs. Importantly, reducing
glycation is beneficial in models of diabetes. On the
other hand, several anti-diabetic drugs act on glyca-
tion [84]. Glycation and, therefore, AGE levels, can
be modulated in different ways: (i) by reducing the
levels of reducing sugars as glucose or dicarbonyls,
which consequently reduces AGE formation; (ii) via
scavenging of the precursors; (iii) or by enhancing
the degradation of dicarbonyls and sugars.
Mitoglitazone (MSDC-016), a drug with anti-
diabetic properties that targets the mitochondrial
pyruvate carrier, a global controller of cell
metabolism, was found to protect against the neuro-
toxic effects of MPP+ in human cells, and against
MPTP in murine, and in nematode models [85].
Remarkably, treatment of mice with mitoglitazone
prior to MPTP administration preserved the motor
function and reduced dopaminergic cell loss, increas-
ing striatal dopamine levels and reducing neuroin-
flammation [85]. These findings are consistent with
studies in human subjects. In a large retrospective
cohort study concluded that diabetic patients treated
with the antidiabetic glitazone drugs presented
reduced incidence of PD [86]. Moreover, glitazone
was also associated with reduced incidence of PD, in
comparison with patients treated only with metformin
[87]. However, the clinical relevance of these findings
is still controversial, as another restrospective cohort
study comparing the incidence of PD in diabetes
patients found that glitazone was not associated with
reduced incidence of PD [88]. Another recent study
analysed the effects of glitazone in PD patients and
found that it did not modify disease progression [89].
Several other studies suggest that anti-diabetic
drugs such as exenatide and metformin are neuro-
protective in several models of PD and in patients
[90, 91]. Metformin and exenatide both act by low-
ering the levels of glucose. In addition, metformin
can also directly scavenge MGO, giving rise to a
non-toxic imidazolinone compound [92].
Importantly, metformin treatment in the MPTP
mouse model of parkinsonism improves motor func-
tion, protects dopaminergic neurons, and increases
levels of the brain derived neurotrophic factor
[93–96]. A trial with diabetes patients revealed that
Glo1 activity was increased after metformin admin-
istration [97].
Telmisartan, an angiotensin II type 1 receptor
antagonist used to manage hypertension, was shown
to be neuroprotective in MPTP models, reduc-
ing degeneration of dopaminergic cells and motor
impairment. In addition, it also reduced aSyn accu-
mulation and increased the levels of BDNF [98–100].
Interestingly, telmisartan was also shown to reduce
AGE levels in the hippocampus of a rat model of
hypertension [98].
Thiamine, also known as vitamin B1, is a cofactor
of enzymes involved in glucose metabolism that was
suggested to be linked to PD [101, 102]. Intramuscu-
lar injection of high-doses of thiamine significantly
improved motor function in PD patients [103, 104].
Interestingly, thiamine was shown to reduce AGE lev-
els in rodent models of diabetes [105] and to reduce
glucose levels in hyperglycemic patients [106].
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Interestingly the MGO-scavengers tenilsetam and
aminoguanidine that both alleviate the toxic effects
of MGO and were considered as anti-diabetic drugs
[107, 108] were shown to reduce aggregation and
improve clearance of aSyn in a PD cell model [74].
In addition, the motor performance in a Drosophila
PD-model [74].
Collectively, these studies provide evidence that
there might be common features between diabetes
and PD, and that additional studies are needed
[69, 107, 109]. We speculate that some of the variabil-
ity may come from the fact that the clinical studies
have not taken into consideration the different sub-
types of PD, and this is something that needs to be
accounted for in future trials, to ensure more conclu-
sive results.
CONCLUDING REMARKS
As discussed above, several studies indicate that
diabetes patients experience an increased risk to
develop PD. However, the underlying molecular
mechanisms are still essentially unknown. Interest-
ingly, both diseases are associated with altered sugar
metabolism and, therefore, with increased levels of
glycation. Glycation is an unavoidable process that
causes the formation of AGEs. These are able to
induce crosslinks between proteins, which could
increase protein aggregation. Since aSyn is a long-
lived protein, AGEs might accumulate in aSyn over
time, affecting its aggregation and toxicity. Inter-
estingly, AGEs were identified in the periphery
of Lewy bodies and aSyn was also found gly-
cated in the brains of PD patients. Glycation was
shown to potentiate aSyn associated neurodegener-
ation in synucleinopathies, suggesting that this could
be the underlying molecular mechanism associating
diabetes and PD.
Importantly, cells evolved different glycation
agents detoxifying mechanisms. Moreover, DJ-1 was
suggested to act both as a methylglyoxalase and as
a deglycase. This connection further supports the
importance of glycation in the etiology of PD.
Given that drugs aiming at decreasing glucose and
AGE levels show protective activity in both PD and
diabetes, it is tempting to further speculate that glyca-
tion may constitute the missing link between PD and
diabetes. Formation of AGEs is, for the most part,
considered irreversible, which underlines the impor-
tance of detecting and treating diabetic conditions at
an early stage. Many questions regarding the sponta-
neous reaction of toxic metabolites with PD-related
proteins still pend resolution, but there is enough
evidence to spark enthusiasm for future studies.
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